BioCentury
ARTICLE | Company News

DNAPrint, Proteos Inc. deal

June 20, 2005 7:00 AM UTC

Proteos, a CRO, will manufacture preclinical batches of DNAP's PT-401 erythropoietin (EPO) dimer to treat anemia. In April, DNAP acquired an exclusive worldwide license to the compound from Beth Israe...